Prospective registry of adult patients receiving therapeutic plasma exchange with a presumptive diagnosis of thrombotic microangiopathy (TMA): The Turkish hematology research and education group (ThREG)-TMA02 study

Basit Öğe Kaydı
dc.authorscopusid14219156500
dc.authorscopusid15756259700
dc.authorscopusid8842895600
dc.authorscopusid6507569757
dc.authorscopusid7202595585
dc.authorscopusid23061033300
dc.authorscopusid6603070081
dc.contributor.authorAkpınar, S.
dc.contributor.authorTekgündüz, E.
dc.contributor.authorErkurt, M.A.
dc.contributor.authorEsen, R.
dc.contributor.authorYılmaz, M.
dc.contributor.authorKarakuş, V.
dc.contributor.authorDemirkan, F.
dc.date.accessioned2022-05-11T14:40:03Z
dc.date.available2022-05-11T14:40:03Z
dc.date.issued2021
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractThrombotic microangiopathy(TMA) is a pathological diagnosis characterized by abnormalities of small vessels leading to microvascular thrombosis of arterioles and capillaries. The current prospective, non-interventional, multicenter (n:18) study aimed to define distribution of different TMA forms in adult Turkish patients who were referred for therapeutic plasma exchange (TPE) for a presumptive diagnosis of TMA. Patients with serum ADAMTS13 activity <5% were diagnosed as acquired thrombotic thrombocytopenic purpura (aTTP). Patients presenting with ADAMTS13 activity 6–10 % / normal renal function and patients with ADAMTS13 activity >10 %, normal renal function and no secondary TMA were treated as unclassified TMA. The study included a total of 97 patients (female: 60; male: 30) with a median age of 48 (18?74). Detailed evaluation at 1 month after hospital admission revealed aTTP, secondary TMA, infection/complement-associated hemolytic uremic syndrome and unclassified TMA in 32 (33 %), 33 (34 %), 26 (27 %) and 6 (6%) patients respectively. As subclassification of various TMAs will dictate specific therapy, proper diagnosis in a timely manner is of utmost clinical significance. © 2021 Elsevier Ltd
dc.description.sponsorshipThe present study was designed as an investigator initiated trial (IIT) and sponsored by Alexion Pharmaceuticals (Tracking number: 100064)
dc.description.sponsorshipAlexion Pharmaceuticals: 100064
dc.identifier.doi10.1016/j.transci.2021.103312
dc.identifier.issn1473-0502
dc.identifier.scopus2-s2.0-85119255512
dc.identifier.scopusqualityQ3
dc.identifier.urihttps://doi.org/10.1016/j.transci.2021.103312
dc.identifier.urihttps://hdl.handle.net/20.500.11776/8846
dc.indekslendigikaynakScopus
dc.institutionauthorAkpınar, Seval
dc.language.isoen
dc.publisherElsevier Ltd
dc.relation.ispartofTransfusion and Apheresis Science
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectHematopoietic cell transplantation
dc.subjectHemolytic uremic syndrome
dc.subjectThrombotic microangiopathy
dc.subjectThrombotic thrombocytopenic purpura
dc.titleProspective registry of adult patients receiving therapeutic plasma exchange with a presumptive diagnosis of thrombotic microangiopathy (TMA): The Turkish hematology research and education group (ThREG)-TMA02 study
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
8846.pdf
Boyut:
683.53 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu